Matching-Adjusted Indirect Comparisons of PARP Inhibitor Combinations in Metastatic Castration-Resistant Prostate Cancer Across Key Populations

Key Points

• To compare the clinical benefits of different PARP inhibitor combinations for treating metastatic castration-resistant prostate cancer (mCRPC).
• Conducted matching-adjusted indirect comparisons (MAICs) between TALA+ENZA, OLAP+AAP, and NIRA+AAP.
• Analyzed various mCRPC populations and treatment endpoints.
• TALA+ENZA showed improved clinical outcomes compared to OLAP+AAP and NIRA+AAP across multiple endpoints.
• Findings support TALA+ENZA as a potential first-line treatment for mCRPC.